Welcome : Guest

RADIOPHARMACEUTICALS - A GLOBAL STRATEGIC BUSINESS REPORT   

Research Abstract

This report analyzes the worldwide markets for Radiopharmaceuticals in US$ Thousand by the following Segments: Diagnostic Radiopharmaceuticals, and Therapeutic Radiopharmaceuticals. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Middle East & Africa and Latin America. Annual estimates and forecasts are provided for the period 2016 through 2024. Also, a five-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 61 companies including many key and niche players such as -

Actinium Pharmaceuticals, Inc.
Alliance Medical
Alseres Pharmaceuticals, Inc.
Avid Radiopharmaceuticals
Bayer HealthCare Pharmaceuticals
Bracco Diagnostics, Inc.

Click here to request a full list of companies covered in the report...

Code: MCP-1889
Price: $4950
Companies: 61
Pages: 310
Date: January 2018
Market Data Tables: 86
  Status: * New Report



TABLE OF CONTENTS


  RADIOPHARMACEUTICALS (Complete Report) Pages : 310   | $4950

   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
  
   Product Definitions and Scope of Study.....I-3  
   A Prelude.....II-11$100
   Current & Future Analysis.....II-21$100
   Diagnostic Radiopharmaceuticals: The Dominant Segment.....II-3
Select Cardiology and Oncology Radiopharmaceuticals.....II-3
1$100
   New Therapeutic Radiopharmaceuticals to Drive Global Market.....II-41$100
   Market Drivers.....II-5
Growing Acceptance in Cancer Treatment.....II-5
Increasing Acceptance of Disease-Targeted Treatment.....II-5
Growing Emphasis of Accurate Diagnosis.....II-5
Expanding Molecular Imaging Applications.....II-5
1$100
   Market Restraints.....II-6
Stringent Regulatory Guidelines for Manufacture, Storage and Usage.....II-6
Global Supply Shortages.....II-6
1$100
   Price Sensitivity & Competition from Alternatives.....II-7
Lack of Dosage Standards for Pediatric Patients Limits Radiopharmaceutical
  Efficacy.....II-7
1$100
   Unfounded Fears of Radiation Exposure Hinder Growth.....II-8
Bottlenecks in Developing Markets.....II-8
Recognition of Intrinsic Cost Benefits: Critical to Market Acceptance.....II-8
Competition.....II-8
1$100
   Relevant Aspects of Radiopharmaceutical Production.....II-91$100
   Increasing Uptake of PET: A Prime Growth Driver.....II-10
Non-Reactor Based TC-99m Production to Drive SPECT Growth.....II-10
1$100
   New Radiopharmaceuticals Drive Adoption of Molecular Imaging.....II-11
PET and SPECT in Cardiovascular Imaging.....II-11
1$100
   Innovative Radiotracers – Key to PET & SPECT Success in Cardiovascular
  Imaging.....II-12
1$100
   Cardiac Amyloidosis Visualization – A Potential Application for PET.....II-13
Application of PET in Drug Development to Expand Opportunities.....II-13
1$100
   Industry Focus Gears up for innovative Radiopharmaceuticals with Therapeutic
  Benefits.....II-14
1$100
   Innovative Radiopharmaceuticals to Boost Cardiac Applications.....II-151$100
   Intra-operative Lymphatic Mapping (ILM): Creates New Opportunities for
  Radiopharmaceuticals in Cancer Detection.....II-16
1$100
   Personalized Medicine to Drive Nuclear Medicine.....II-17
Table 1: Drug Ineffectiveness for Select Therapeutic Categories as a Percentage of Patient Population (includes corresponding Graph/Chart).....II-17
2$350
   Rise in Incidence of Neurological Disorders to Drive Growth.....II-19
Battling Alzheimer’s Disease – A Powerful Market Force for Nuclear Medicine.....II-19
1$100
   Combating the Shortage of RadioIsotopes.....II-202$200
   Rise in Incidence of Cancer – A Major Growth Driver.....II-22
Cancer Prone Sites based on Age.....II-22
1$100
   Table 2: Cancer Incidence in Developed Nations by Site: 2012 (includes corresponding Graph/Chart).....II-231$350
   Ageing Population – A Vital Demography.....II-24 1$100
   Table 3: Global Population Statistics for the 65+ Age Group (2015) (includes corresponding Graph/Chart).....II-251$350
   Table 4: Comparison of Aging Population by Country (1980, 2015 & 2050): Percentage Share of Population Aged Above-65 Years of the Overall Population for Select Countries (includes corresponding Graph/Chart).....II-261$350
   Global CVD Stats.....II-27
Table 5: Global Estimated Fatalities by Heart Conditions - Percentage Share Breakdown for Ischemic Heart Disease, Stroke, CVD, and Others (includes corresponding Graph/Chart).....II-27

Table 6: Projected Fatalities in Low Income Countries by Disease (2015 & 2030): Percentage Share Breakdown of Number of Deaths for CVD; Cancer; Injury; HIV, TB & Malaria; Malnutrition; and Others (includes corresponding Graph/Chart).....II-27
1$350
   Table 7: Projected Fatalities in Mid Income Countries by Disease (2015 & 2030): Percentage Share Breakdown of Number of Deaths for CVD; Cancer; Injury; HIV, TB & Malaria; Malnutrition; and Others (includes corresponding Graph/Chart).....II-281$350
   Radiopharmaceuticals: A Definition.....II-29
Mechanism of Action.....II-29
Application of Radiopharmaceuticals.....II-29
Radioactive Tracers for Diagnostic Imaging.....II-29
1$100
   Therapeutics.....II-30
Research.....II-30
Sterilization.....II-30
Classification of Radiopharmaceuticals.....II-30
Diagnostic Radiopharmaceuticals.....II-30
Commonly Used Diagnostic Radiopharmaceutical Agents.....II-30
1$100
   Major Isotopes and their Diagnostic Applications.....II-311$100
   Advantages.....II-32
Classification.....II-32
Cardiology Diagnostics.....II-32
Non-cardiology Diagnostics.....II-32
Molecular Imaging Modalities in Radiopharmaceutical Diagnostics.....II-32
Planar Imaging.....II-32
1$100
   Positron Emission Tomography (PET).....II-33
Applications of PET.....II-33
1$100
   Commonly used Radioisotopes in PET Scans.....II-34
Major PET Isotopes and their Applications.....II-34
1$100
   Single Photon Emission Computed Tomography (SPECT).....II-35
Applications of SPECT.....II-35
Commonly used Radioisotopes in SPECT Scans.....II-35
Therapeutic Radiopharmaceuticals.....II-35
1$100
   Characteristics of Therapeutic Radiopharmaceuticals.....II-36
Commonly used Therapeutic Agents.....II-36
1$100
   Major Isotopes and their Therapeutic Applications.....II-37
Note on Select Commercially Available Therapeutic Radiopharmaceuticals.....II-37
1$100
   ORA Launches NEPTIS® xSeed™ Kitless Synthesizer.....II-38
Advanced Accelerator Applications Resubmits NDA for Lutathera®.....II-38
Norgine B.V. Launches LYMPHOSEEK®.....II-38
IBA launches the Fixed IFP™.....II-38
Piramal Imaging and ISOLOGIC Innovative Radiopharmaceuticals Receive Approval.....II-38
FDA Approves Netspot to Detect Rare Neuroendocrine Tumors.....II-38
1$100
   Blue Earth Diagnostics Bags FDA Approval for AxuminTM.....II-39
EMA Issues Positive Opinion on Marketing Authorization Application for SomaKit
  TOC.....II-39
IBA Unveils the Cyclone KIUBE Cyclotron.....II-39
Advanced Accelerator Expands NETSPOTTM Supply Chain.....II-39
Blue Earth Diagnostics and Siemens’ PETNET Solutions Introduce AxuminTM (Fluciclovine F
  18) Injection.....II-39
Blue Earth Wins FDA Approval for PET Agent for Axumin.....II-39
1$100
   Zevacor to Develop SomaKit-TATE doses for AAA.....II-40
Triad Isotopes Receives FDA Approval for Fludeoxyglucose F18 (18F FDG) and Sodium
  Fluoride F-18......II-40
Zevacor Wins FDA Approval of ANDA for Choline C11.....II-40
Advanced Medical Isotope Receives FDA Clearance for Y-90 RadioGel™ Device.....II-40
Sumitomo Heavy Industries Receives Medical Device Approval for MPS200Aß.....II-40
NorthStar Medical Radioisotopes to Start Production of Molybdenum-99.....II-40
GE Healthcare Launches GENtraceTM and FASTlab™ 2 for Radiopharmaceutical
  Manufacturing.....II-40
1$100
   RadioMedix Introduces SmartMedix™ Synthesizers.....II-41
Lantheus Medical Imaging Gains FDA Approval for manufacturing NEUROLITE® at Jubilant
  HollisterStier.....II-41
1$100
   Telix Pharmaceuticals and ANMI Enter into Partnership for Commercialization of
  ANMI’s 68Ga-HBED-CC-PSMA Kit.....II-42
Telix Pharmaceuticals Signs Technology Licensing Agreement and Research Collaboration
  with the University of Melbourne.....II-42
RadioMedix and ITM Enhter into Partnership Agreement for Distribution of Lutetium-177
  in North America.....II-42
Blue Earth Diagnostics Signs Exclusive Distribution Agreement with Seibersdorf
  Laboratories for the supply of Axumin®.....II-42
Blue Earth Diagnostics and GE Healthcare Sign Agreement to Manufacture Axumin®.....II-42
IRE-ELiT Signs Exclusive Long-Term Contract with Cardinal Health.....II-42
1$100
   Jubilant Acquires Radiopharmacy Business of Triad.....II-43
ARTMS Products and GE Healthcare Partner to Expand Cyclotron-Produced
  Radioisotopes.....II-43
Theragnostics Signs Partnership Agreement with ROTOP.....II-43
Cyclotek and Telix Pharmaceuticals Sign Radiopharmaceutical Manufacturing
  Agreement.....II-43
IBA and Philips Collaborate for Sales and Marketing of Proton Therapy in
  Brazil.....II-43
Advanced Accelerator Applications Signs Agreement with Blue Earth Diagnostics to Supply
  Axumin™.....II-43
ARTMS Products Partners with Alliance Medical to Supply Tc-99m.....II-43
Sofie Biosciences to Acquire Zevacor Pharma.....II-43
1$100
   IBA Molecular and Mallinckrodt Nuclear Medicine Merge to Form Curium.....II-44
GE Healthcare to Supply Radiopharmaceuticals to HealthTrust.....II-44
IBA Signs Co-Marketing Agreement in North America with Nelco Worldwide.....II-44
Telix Announces Product Development Partnership with Therapeia.....II-44
IBA Signs Proteus®ONE Contracts with Proton Partners International.....II-44
Cellectar Biosciences Selects Hamilton for Supply of CLR 131.....II-44
Life Healthcare Acquires Alliance Medical Group.....II-44
1$100
   Lantheus Holdings Divests its Australian Radiopharmacy Servicing Business.....II-45
ITEL Signed Agreement with AAA to Manufacture and Commercialize F-18
  Radiopharmaceuticals.....II-45
Zevacor Pharmato Manufacture and Supply Lomab-B for Pivotal Phase 3 SIERRA
  Trial.....II-45
Blue Earth Diagnostics and Norsk Enter into Manufacturing and Distribution
  partnership for Fluciclovine (18F).....II-45
Ipsen and 3B Pharmaceuticals Sign Exclusive License Agreement to Develop Novel
  Radiopharmaceuticals in Oncology.....II-45
Isologic Acquires Lantheus Medical Imaging Canadian Radiopharmaceutical
  Business.....II-45
IRE ELiT & Monrol Sign Distribution Agreement for Galli Eo™.....II-45
1$100
   Westinghouse Signs Agreement with NorthStar for Production of Medical
  Radioisotopes.....II-46
Advanced Medical Enters into Collaboration with IsoTherapeutics to.....II-46
ISOLOGIC Opens New Cyclotron and Radiopharmaceutical Manufacturing Facility.....II-46
IBA Divests IBA Molecular North America Business to Illinois Health and
  Science.....II-46
AAA Enters into Distribution Agreement with FUJIFILM RI Pharma for Lutathera in
  Japan.....II-46
Piramal Imaging Signs Strategic Partnership with ISOLOGIC for Exclusive
  Commercialization of Neuraceq in Canada.....II-46
Ipsen to Acquire OctreoPharm Sciences.....II-46
1$100
   RadioMedix Enters into agreement with AREVA Med to Develop a Novel Treatment against
  Neuroendocrine Tumors.....II-47
Siemens’ PETNET Solutions to Manufacture and Distribute Blue Earth’s Fluciclovine
  (18F).....II-47
IBA to Sell U.S. Operations to Illinois Health and Science.....II-47
Lantheus Medical Signs agreement with IRE for supply of Xenon Xe 133 Gas.....II-47
INR Receives U.S. Patent for Radiostrontium Production Technology.....II-47
1$100
   Actinium Pharmaceuticals, Inc. (USA).....II-48
Alliance Medical (UK).....II-48
Alseres Pharmaceuticals, Inc. (USA).....II-48
1$100
   Avid Radiopharmaceuticals (USA).....II-49
Bayer HealthCare Pharmaceuticals (Germany).....II-49
Bracco Diagnostics, Inc. (USA).....II-49
1$100
   Cardinal Health, Inc. (USA).....II-50
GE Healthcare (UK).....II-50
1$100
   Ion Beam Applications S.A (Belgium).....II-51
Immunomedics, Inc. (USA).....II-51
1$100
   Jubilant Pharma (India).....II-52
Lantheus Medical Imaging Inc. (USA).....II-52
1$100
   Medi-Radiopharma Ltd (Hungary).....II-53
Nordion, Inc. (Canada).....II-53
1$100
   Peregrine Pharmaceuticals, Inc. (USA).....II-54
PETNET Solutions Inc. (USA).....II-54
1$100
   Positron Corporation (USA).....II-55
Triad Isotopes, Inc. (USA).....II-55
1$100
   Table 8: World Recent Past, Current & Future Analysis for Radiopharmaceuticals by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Middle East & Africa and Latin American Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart).....II-561$350
   Table 9: World Historic Review for Radiopharmaceuticals by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Middle East & Africa and Latin American Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-571$350
   Table 10: World 14-Year Perspective for Radiopharmaceuticals by Geographic Region - Percentage Breakdown of Value Sales for US, Canada, Japan, Europe, Asia-Pacific, Middle East & Africa and Latin American Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart).....II-581$350
   Table 11: World Recent Past, Current & Future Analysis for Diagnostic Radiopharmaceuticals by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Middle East & Africa and Latin American Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart).....II-591$350
   Table 12: World Historic Review for Diagnostic Radiopharmaceuticals by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Middle East & Africa and Latin American Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-601$350
   Table 13: World 14-Year Perspective for Diagnostic Radiopharmaceuticals by Geographic Region - Percentage Breakdown of Value Sales for US, Canada, Japan, Europe, Asia-Pacific, Middle East & Africa and Latin American Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart).....II-611$350
   Table 14: World Recent Past, Current & Future Analysis for Therapeutic Radiopharmaceuticals by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Middle East & Africa and Latin American Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart).....II-621$350
   Table 15: World Historic Review for Therapeutic Radiopharmaceuticals by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Middle East & Africa and Latin American Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-631$350
   Table 16: World 14-Year Perspective for Therapeutic Radiopharmaceuticals by Geographic Region - Percentage Breakdown of Value Sales for US, Canada, Japan, Europe, Asia-Pacific, Middle East & Africa and Latin American Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart).....II-641$350
   A. Market Analysis.....III-1
Outlook.....III-1
Radioisotope/Radiopharmaceuticals Production Scenario.....III-1
1$75
   Rise in Diagnostic Applications Stimulate Future Growth.....III-2
Table 17: US Market for Diagnostic Radiopharmaceuticals by Modality (2016): Percentage Breakdown of Value Sales for PET and SPECT (includes corresponding Graph/Chart).....III-2
1$200
   Table 18: US Market for Diagnostic Radiopharmaceuticals Agents (2016): Percentage Share Breakdown of Value Sales for Cardiology and Non-Cardiology Applications (includes corresponding Graph/Chart).....III-3
Demographic Changes Offer Growth Opportunities.....III-3
1$200
   Table 19: North American Aging Population by Age Group: 1975-2050 (includes corresponding Graph/Chart).....III-4
Rising Incidence of Cancer - A Major Growth Driver.....III-4
1$200
   Table 20: New Cancer Cases by Gender and Affected Site in the US (2017E) (includes corresponding Graph/Chart).....III-51$200
   Cardiovascular Imaging to Lead Volume Growth.....III-6
Focused R&D Efforts to Fuel Therapeutic Radiopharmaceuticals Market.....III-6
Radiopharmaceuticals in PET Imaging – Prospects.....III-6
1$75
   Isotope Shortage Leads to Dependence on Imports.....III-7
US Fluorodeoxyglucose (FDG) Market.....III-7
Product Launches.....III-7
2$150
   Strategic Corporate Developments.....III-92$150
   Select Players.....III-115$375
   B. Market Analytics.....III-16
Table 21: US Recent Past, Current & Future Analysis for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart).....III-16
1$200
   Table 22: US Historic Review for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-171$200
   Table 23: US 14-Year Perspective for Radiopharmaceuticals by Segment - Percentage Breakdown of Value Sales for Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart).....III-181$200
   A. Market Analysis.....III-19
Outlook.....III-19
Canadian Scientists Gear up to find Remedy for Mo-99 Supply Shortages.....III-19
1$75
   An Overview of Medical Imaging Market.....III-20
Regulatory and Legal Restrictions.....III-20
Strategic Corporate Developments.....III-20
1$75
   Select Players.....III-211$75
   B. Market Analytics.....III-22
Table 24: Canadian Recent Past, Current & Future Analysis for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart).....III-22
1$200
   Table 25: Canadian Historic Review for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-231$200
   Table 26: Canadian 14-Year Perspective for Radiopharmaceuticals by Segment - Percentage Breakdown of Value Sales for Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart).....III-241$200
   A. Market Analysis.....III-25
Outlook.....III-25
Healthcare in Japan.....III-25
Strategic Corporate Developments.....III-25
1$75
   B. Market Analytics.....III-26
Table 27: Japanese Recent Past, Current & Future Analysis for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart).....III-26
1$200
   Table 28: Japanese Historic Review for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-271$200
   Table 29: Japanese 14-Year Perspective for Radiopharmaceuticals by Segment - Percentage Breakdown of Value Sales for Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart).....III-281$200
   A. Market Analysis.....III-29
Outlook.....III-29
New Applications and Products Augur Good Market Prospects.....III-29
1$75
   B. Market Analytics.....III-30
Table 30: European Recent Past, Current & Future Analysis for Radiopharmaceuticals by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart).....III-30
1$200
   Table 31: European Historic Review for Radiopharmaceuticals by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-311$200
   Table 32: European 14-Year Perspective for Radiopharmaceuticals by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart).....III-321$200
   Table 33: European Recent Past, Current & Future Analysis for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart).....III-331$200
   Table 34: European Historic Review for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-341$200
   Table 35: European 14-Year Perspective for Radiopharmaceuticals by Segment - Percentage Breakdown of Value Sales for Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart).....III-351$200
   A. Market Analysis.....III-36
Outlook.....III-36
Strategic Corporate Developments.....III-36
1$75
   B. Market Analytics.....III-37
Table 36: French Recent Past, Current & Future Analysis for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart).....III-37
1$200
   Table 37: French Historic Review for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-381$200
   Table 38: French 14-Year Perspective for Radiopharmaceuticals by Segment - Percentage Breakdown of Value Sales for Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart).....III-391$200
   A. Market Analysis.....III-40
Outlook.....III-40
Strategic Corporate Developments.....III-40
1$75
   Key Player.....III-411$75
   B. Market Analytics.....III-42
Table 39: German Recent Past, Current & Future Analysis for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart).....III-42
1$200
   Table 40: German Historic Review for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-431$200
   Table 41: German 14-Year Perspective for Radiopharmaceuticals by Segment - Percentage Breakdown of Value Sales for Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart).....III-441$200
   A. Market Analysis.....III-45
Outlook.....III-45
Strategic Corporate Development.....III-45
1$75
   B. Market Analytics.....III-46
Table 42: Italian Recent Past, Current & Future Analysis for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart).....III-46
1$200
   Table 43: Italian Historic Review for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-471$200
   Table 44: Italian 14-Year Perspective for Radiopharmaceuticals by Segment - Percentage Breakdown of Value Sales for Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart).....III-481$200
   A. Market Analysis.....III-49
Outlook.....III-49
Strategic Corporate Development.....III-49
1$75
   Select Players.....III-501$75
   B. Market Analytics.....III-51
Table 45: UK Recent Past, Current & Future Analysis for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart).....III-51
1$200
   Table 46: UK Historic Review for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-521$200
   Table 47: UK 14-Year Perspective for Radiopharmaceuticals by Segment - Percentage Breakdown of Value Sales for Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart).....III-531$200
   Market Analysis.....III-54
Table 48: Spanish Recent Past, Current & Future Analysis for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart).....III-54
1$200
   Table 49: Spanish Historic Review for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-551$200
   Table 50: Spanish 14-Year Perspective for Radiopharmaceuticals by Segment - Percentage Breakdown of Value Sales for Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart).....III-561$200
   A. Market Analysis.....III-57
Outlook.....III-57
B. Market Analytics.....III-57
Table 51: Russian Recent Past, Current & Future Analysis for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart).....III-57
1$200
   Table 52: Russian Historic Review for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-581$200
   Table 53: Russian 14-Year Perspective for Radiopharmaceuticals by Segment - Percentage Breakdown of Value Sales for Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart).....III-591$200
   A. Market Analysis.....III-60
Outlook.....III-60
Market Overview.....III-60
Product Innovations/Introductions.....III-60
1$75
   Strategic Corporate Developments.....III-611$75
   Select Players.....III-621$75
   B. Market Analytics.....III-63
Table 54: Rest of Europe Recent Past, Current & Future Analysis for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart).....III-63
1$200
   Table 55: Rest of Europe Historic Review for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-641$200
   Table 56: Rest of Europe 14-Year Perspective for Radiopharmaceuticals by Segment - Percentage Breakdown of Value Sales for Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart).....III-651$200
   A. Market Analysis.....III-66
Outlook.....III-66
1$75
   B. Market Analytics.....III-67
Table 57: Asia-Pacific Recent Past, Current & Future Analysis for Radiopharmaceuticals by Geographic Region - China, India and Rest of Asia-Pacific Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart).....III-67
1$200
   Table 58: Asia-Pacific Historic Review for Radiopharmaceuticals by Geographic Region - China, India and Rest of Asia-Pacific Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-681$200
   Table 59: Asia-Pacific 14-Year Perspective for Radiopharmaceuticals by Geographic Region - Percentage Breakdown of Value Sales for China, India and Rest of Asia-Pacific Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart).....III-691$200
   Table 60: Asia-Pacific Recent Past, Current & Future Analysis for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart).....III-701$200
   Table 61: Asia-Pacific Historic Review for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-711$200
   Table 62: Asia-Pacific 14-Year Perspective for Radiopharmaceuticals by Segment - Percentage Breakdown of Value Sales for Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart).....III-721$200
   Market Analysis.....III-73
Table 63: Chinese Recent Past, Current & Future Analysis for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart).....III-73
1$200
   Table 64: Chinese Historic Review for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-741$200
   Table 65: Chinese 14-Year Perspective for Radiopharmaceuticals by Segment - Percentage Breakdown of Value Sales for Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart).....III-751$200
   A. Market Analysis.....III-76
Outlook.....III-76
Key Player.....III-76
1$75
   B. Market Analytics.....III-77
Table 66: Indian Recent Past, Current & Future Analysis for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart).....III-77
1$200
   Table 67: Indian Historic Review for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-781$200
   Table 68: Indian 14-Year Perspective for Radiopharmaceuticals by Segment - Percentage Breakdown of Value Sales for Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart).....III-791$200
   A. Market Analysis.....III-80
Outlook.....III-80
Strategic Corporate Development.....III-80
Key Player.....III-80
1$75
   B. Market Analytics.....III-81
Table 69: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart).....III-81
1$200
   Table 70: Rest of Asia-Pacific Historic Review for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-821$200
   Table 71: Rest of Asia-Pacific 14-Year Perspective for Radiopharmaceuticals by Segment - Percentage Breakdown of Value Sales for Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart).....III-831$200
   Market Analysis.....III-84
Table 72: Middle East & Africa Recent Past, Current & Future Analysis for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart).....III-84
1$200
   Table 73: Middle East & Africa Historic Review for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-851$200
   Table 74: Middle East & Africa 14-Year Perspective for Radiopharmaceuticals by Segment - Percentage Breakdown of Value Sales for Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart).....III-861$200
   A. Market Analysis.....III-87
Outlook.....III-87
B. Market Analytics.....III-87
Table 75: Latin American Recent Past, Current & Future Analysis for Radiopharmaceuticals by Region - Brazil and Rest of Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart).....III-87
1$200
   Table 76: Latin American Historic Review for Radiopharmaceuticals by Region - Brazil and Rest of Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-881$200
   Table 77: Latin American 14-Year Perspective for Radiopharmaceuticals by Region - Percentage Breakdown of Value Sales for Brazil and Rest of Latin America Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart).....III-891$200
   Table 78: Latin American Recent Past, Current & Future Analysis for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart).....III-901$200
   Table 79: Latin American Historic Review for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-911$200
   Table 80: Latin American 14-Year Perspective for Radiopharmaceuticals by Segment - Percentage Breakdown of Value Sales for Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart).....III-921$200
   A. Market Analysis.....III-93
Outlook.....III-93
Strategic Corporate Development.....III-93
1$75
   B. Market Analytics.....III-94
Table 81: Brazilian Recent Past, Current & Future Analysis for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart).....III-94
1$200
   Table 82: Brazilian Historic Review for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-951$200
   Table 83: Brazilian 14-Year Perspective for Radiopharmaceuticals by Segment - Percentage Breakdown of Value Sales for Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart).....III-961$200
   Market Analysis.....III-97
Table 84: Rest of Latin America Recent Past, Current & Future Analysis for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart).....III-97
1$200
   Table 85: Rest of Latin America Historic Review for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-981$200
   Table 86: Rest of Latin America 14-Year Perspective for Radiopharmaceuticals by Segment - Percentage Breakdown of Value Sales for Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart).....III-991$200
  
Total Companies Profiled: 61 (including Divisions/Subsidiaries - 69)

Region/Country Players

The United States 27 Canada 4 Japan 1 Europe 28 France 4 Germany 5 The United Kingdom 4 Italy 2 Rest of Europe 13 Asia-Pacific (Excluding Japan) 8 Africa 1
Click here to request a full table of contents and more details on this project.